ABCL

AbCellera Biologics Inc.
CAPPED RATING

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

AbCellera Biologics Inc. (ABCL) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (D). The rating has held at C+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
B
Factor Score 3.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -15.7
EV / EBITDA -17.1
Rev Growth YoY -76.3%
Gross Margin N/M
Price Return 3M 0.0%
Price Return 12M 207.2%
Catalyst Signal 0.00
Market Cap $3.6B
TTM Revenue $66.2M
Price / Sales 54.9
ROE -17.3%

Historical Factor Score Progression

Held C+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.7) D (1.3) C+ (2.6) B (3.5) C+ (2.6) C+ (2.5)
2026-11-10 C+ (2.6) D (1.3) C+ (2.6) A- (4.1) C+ (2.6) C+ (2.6)
2026-11-03 C+ (2.7) D (1.2) C+ (2.6) A+ (5.0) C+ (2.7) C+ (2.8)
2026-10-27 C+ (2.7) D (1.2) C+ (2.7) A+ (4.9) C+ (2.6) C+ (2.8)
2026-10-20 C+ (2.7) D (1.2) C+ (2.7) A+ (4.9) C+ (2.6) C+ (2.8)
Page 1 of 8
…